CIK 0001785279
- Emerging growth company
Metagenomi Therapeutics, Inc.
Sign in to watch- Ticker
- MGX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 813909017
- Phone
- +1 510-871-4880
- Business address
- 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, CA, 94608
- Former names
- Metagenomi, Inc., Metagenomi Technologies, LLC
- 4 Open-market sale Chief Executive Officer sold 1,602 shares at $1.77 ($2,839)
- 4 Open-market sale Director sold 2,701 shares at $1.81 ($4,889)
- 4 Open-market sale Chief Financial Officer sold 1,576 shares at $1.81 ($2,853)
- 4 Open-market sale Chief Executive Officer sold 1,602 shares at $1.81 ($2,900)
- 4 Open-market sale Wein Matthew sold 199 shares at $1.81 ($360)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Wein Matthew sold 199 shares at $1.75 ($348)
- 4 Open-market sale Chief Medical Officer sold 5,239 shares at $1.75 ($9,168)
- 4 Open-market sale Chief Financial Officer sold 1,576 shares at $1.75 ($2,758)
- 4 Open-market sale Chief Executive Officer sold 10,785 shares at $1.75 ($18,874)
- 4 Open-market sale Irish Jian sold 6,390 shares at $1.75 ($11,183)
- 4 Grant or award Chief Financial Officer acquired 14,000 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 32,000 shares (grant or award)
- 4 Grant or award Irish Jian acquired 23,000 shares (grant or award)
- 4 Grant or award Wein Matthew acquired 7,425 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 14,000 shares (grant or award)
Page 2 of 4 · 73 filings